Medicom takeover to bolster Phillips-Medisize's drug delivery solutions

 
“This transaction is consistent with our strategic focus on serving the rapidly growing diabetes, biologics, specialty pharmaceutical and personalised oncology markets that need these products and reinforces our leading position in drug delivery device solutions. Medicom’s impressive solutions, 25 years of expertise and over 100 state-of-the-art technology accelerators, coupled with Phillips-Medisize’s scale in design to manufacturing of high to low volume production drug delivery devices, will provide customers with end-to-end integrated service solutions, resulting in increased speed to market,” said Matt Jennings, chairman, CEO and president of Phillips-Medisize.
 
With expertise in advanced moulding and assembly, Phillips-Medisize has become one of the leading global players in medical device and diagnostics, drug delivery, primary pharmaceutical packaging, and commercial markets. The company has annual sales of over $650 million with 80 percent of the total revenue coming from drug delivery, medical device and diagnostic products, such as: disposable insulin pens, glucose meters, specialty inhalation drug delivery devices, single-use surgical devices and consumable diagnostic components.